Tag Archives: Tests & Procedures

Surgeons successfully transplant genetically modified pig heart into human patient

Posted on by

In a desperate effort to save the life of a 57-year-old man, doctors at the University of Maryland School of Medicine have accomplished a medical first. Per The Associated Press, this past Friday, surgeons successfully transplanted a pig heart into a patient as part of an experimental procedure.

In doing so, they showed a genetically modified animal organ could survive and function within the human body without immediate rejection. Three days after the procedure, David Bennett, the individual who underwent the surgery, is alive and “doing well,” according to the hospital.

The Food and Drug Administration authorized the procedure on compassionate grounds. Bennett was ineligible for a traditional heart transplant and had run out of other options. “It was either die or do this transplant. I want to live. I know it’s a shot in the dark, but it’s my last choice,” he said in a statement before doctors operated on him.

Scientists have tried to save humans with animal organs for decades. One of the most notable attempts occurred in 1984 when doctors grafted a baboon heart into Stephanie Fae Beauclair, an infant born with hypoplastic left heart syndrome. The congenital disorder left her body incapable of circulating blood properly. Baby Fae, as she was better known, survived for 21 days before her body eventually rejected the transplanted organ.

According to The New York Times, what makes this latest procedure different is doctors used a heart that had been genetically modified to remove four genes that encode a molecule that causes the body to reject the orphan organ. They also inserted six human genes to make the immune system more tolerable of the foreign tissue. Whether the experiment represents a breakthrough will depend on what happens next. Bennett’s body could still reject the pig heart. For the moment, however, he’s alive, and doctors are understandably excited about what this could mean for patients.

“If this works, there will be an endless supply of these organs for patients who are suffering,” Dr. Muhammad Mohiuddin, scientific director of the University of Maryland School of Medicine’s xenotransplantation program, told The Associated Press. That would be a dramatic change from the status quo. According to the Health Resources and Services Administration, more than 100,000 people are on the national transplant waiting list, and 17 individuals die every day waiting for an organ transplant.

Surgeons successfully transplant genetically modified pig heart into human patient

Posted on by

In a desperate effort to save the life of a 57-year-old man, doctors at the University of Maryland School of Medicine have accomplished a medical first. Per The Associated Press, this past Friday, surgeons successfully transplanted a pig heart into a patient as part of an experimental procedure.

In doing so, they showed a genetically modified animal organ could survive and function within the human body without immediate rejection. Three days after the procedure, David Bennett, the individual who underwent the surgery, is alive and “doing well,” according to the hospital.

The Food and Drug Administration authorized the procedure on compassionate grounds. Bennett was ineligible for a traditional heart transplant and had run out of other options. “It was either die or do this transplant. I want to live. I know it’s a shot in the dark, but it’s my last choice,” he said in a statement before doctors operated on him.

Scientists have tried to save humans with animal organs for decades. One of the most notable attempts occurred in 1984 when doctors grafted a baboon heart into Stephanie Fae Beauclair, an infant born with hypoplastic left heart syndrome. The congenital disorder left her body incapable of circulating blood properly. Baby Fae, as she was better known, survived for 21 days before her body eventually rejected the transplanted organ.

According to The New York Times, what makes this latest procedure different is doctors used a heart that had been genetically modified to remove four genes that encode a molecule that causes the body to reject the orphan organ. They also inserted six human genes to make the immune system more tolerable of the foreign tissue. Whether the experiment represents a breakthrough will depend on what happens next. Bennett’s body could still reject the pig heart. For the moment, however, he’s alive, and doctors are understandably excited about what this could mean for patients.

“If this works, there will be an endless supply of these organs for patients who are suffering,” Dr. Muhammad Mohiuddin, scientific director of the University of Maryland School of Medicine’s xenotransplantation program, told The Associated Press. That would be a dramatic change from the status quo. According to the Health Resources and Services Administration, more than 100,000 people are on the national transplant waiting list, and 17 individuals die every day waiting for an organ transplant.

FDA clears Synchron’s brain-computer interface device for human trials

Posted on by

A company that makes an implantable brain-computer interface (BCI) has been given the go-ahead by the Food and Drug Administration to run a clinical trial with human patients. Synchron plans to start an early feasibility study of its Stentrode implant later this year at Mount Sinai Hospital, New York with six subjects. The company said it will assess the device's "safety and efficacy in patients with severe paralysis."

Synchron received the FDA's green light ahead of competitors like Elon Musk’s Neuralink. Before such companies can sell BCIs commercially in the US, they need to prove that the devices work and are safe. The FDA will provide guidance for trials of BCI devices for patients with paralysis or amputation during a webinar on Thursday.

Another clinical trial of Stentrode is underway in Australia. Four patients have received the implant, which is being used "for data transfer from motor cortex to control digital devices," Synchron said. According to data published in the Journal of NeuroInterventional Surgery, two of the patients were able to control their computer with their thoughts. They completed work-related tasks, sent text messages and emails and did online banking and shopping.

It takes around two hours to implant a Stentrode device with a minimally invasive procedure, according to Synchron. The device is implanted through a blood vessel at the bottom of the neck and maneuvered into the brain. Synchron CEO Thomas Oxley told Bloomberg the device could be available to buy within three to five years.

A magnetic helmet shrunk a deadly tumor in world-first test

Posted on by

We've seen helmets and AI that can spot brain tumors, but a new hard hat can actually treat them, too. As part of the latest neurological breakthrough, researchers used a helmet that generates a magnetic field to shrink a deadly tumor by a third. The 53-year-old patient who underwent the treatment ultimately passed away due to an unrelated injury. But, an autopsy of his brain showed that the procedure had removed 31 percent of the tumor mass in a short time. The test marked the first noninvasive therapy for a deadly form of brain cancer known as glioblastoma.

The helmet features three rotating magnets connected to a microprocessor-based electronic controller operated by a rechargeable battery. As part of the therapy, the patient wore the device for five weeks at a clinic and then at home with the help of his wife. The resulting magnetic field therapy created by the helmet was administered for two hours initially and then ramped up to a maximum of six hours per day. During the period, the patient's tumor mass and volume shrunk by nearly a third, with shrinkage appearing to correlate with the treatment dose.

The inventors of the device — which received FDA approval for compassionate use treatment — claim it could one day help treat brain cancer without radiation or chemotherapy. “Our results...open a new world of non-invasive and nontoxic therapy...with many exciting possibilities for the future,” said David S. Baskin, corresponding author and director of the Kenneth R. Peak Center for Brain and Pituitary Tumor Treatment in the Department of Neurosurgery at Houston Methodist Neurological Institute. Details of the procedure have been published in the peer-reviewed journal Frontiers in Oncology.

A magnetic helmet shrunk a deadly tumor in world-first test

Posted on by

We've seen helmets and AI that can spot brain tumors, but a new hard hat can actually treat them, too. As part of the latest neurological breakthrough, researchers used a helmet that generates a magnetic field to shrink a deadly tumor by a third. The 53-year-old patient who underwent the treatment ultimately passed away due to an unrelated injury. But, an autopsy of his brain showed that the procedure had removed 31 percent of the tumor mass in a short time. The test marked the first noninvasive therapy for a deadly form of brain cancer known as glioblastoma.

The helmet features three rotating magnets connected to a microprocessor-based electronic controller operated by a rechargeable battery. As part of the therapy, the patient wore the device for five weeks at a clinic and then at home with the help of his wife. The resulting magnetic field therapy created by the helmet was administered for two hours initially and then ramped up to a maximum of six hours per day. During the period, the patient's tumor mass and volume shrunk by nearly a third, with shrinkage appearing to correlate with the treatment dose.

The inventors of the device — which received FDA approval for compassionate use treatment — claim it could one day help treat brain cancer without radiation or chemotherapy. “Our results...open a new world of non-invasive and nontoxic therapy...with many exciting possibilities for the future,” said David S. Baskin, corresponding author and director of the Kenneth R. Peak Center for Brain and Pituitary Tumor Treatment in the Department of Neurosurgery at Houston Methodist Neurological Institute. Details of the procedure have been published in the peer-reviewed journal Frontiers in Oncology.